Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227593 | 0.85 | CA1 (0.62) | ARAURKAKDRAURKBCA1 | |
| SCHEMBL6978659 | 0.80 | BRAF (0.57) | ARAURKAKDRAURKBBRD4 | |
| SCHEMBL4650966 | 0.80 | AR (0.66) | ARAURKAKDRAURKBBRD4 | |
| SCHEMBL14588787 | 0.79 | HDAC1 (0.54) | AURKAKDRAURKBCA1CA2 | |
| SCHEMBL1403318 | 0.79 | GAA (0.52) | ARAURKAKDRAURKBCA1 | |
| SCHEMBL5778734 | 0.79 | AURKA (0.45) | ARAURKAKDRAURKBBRD4 | |
| SCHEMBL28609831 | 0.77 | MEN1 (0.56) | AURKAKDRAURKBBRD4SMN1; SMN2 | |
| SCHEMBL1403147 | 0.77 | HDAC1 (0.54) | LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10345020 | 0.76 | BRD4 (0.52) | ARAURKAKDRAURKBBRD4 | |
| SCHEMBL8861660 | 0.76 | BRD4 (0.52) | ARAURKAKDRAURKBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541276-B2 | Nucleophilic reaction of alkoxyamine | VERSICOR, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6448058-B1 | METHOD OF INHIBITING A PEPTIDE DEFORMYLASE, THE METHOD COMPRISING CONTACTING THE PEPTIDE DEFORMYLASE WITH ONE OR MORE COMPOUNDS OF THE INVENTION | VERSICOR, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010053555-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. | 2001-12-20 | — | — | US | disclosed |
| US-6281245-B1 | ADMINISTERING DEFORMYLASE INHIBITOR | VERSICOR, INC. | 2001-08-28 | — | — | US | disclosed |
| WO-1999057097-A2 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053555-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | HNMT, HAAO, HPSE | AR 3339/4885AURKA 1181/4885KDR 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.